This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dulaimi, E. Articles by Cairns, P. Search for Related Content PubMed PubMed Citation Articles by Dulaimi, E. Articles by Cairns, P.

Promoter Hypermethylation Profile of Kidney Cancer

Departments of ¹ Surgical Oncology, ² Pathology, and ³ Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ⁴ Division of Urology Duke University Medical Center, Durham, North Carolina; and ⁵ Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama

ABSTRACT

Purpose: Promoter hypermethylation is an important mechanism of inactivation of tumor suppressor genes in cancer cells. Kidney tumors are heterogeneous in their histology, genetics, and clinical behavior. To gain insight into the role of epigenetic silencing of tumor suppressor and cancer genes in kidney tumorigenesis, we determined a hypermethylation profile of kidney cancer.

Experimental Design: We examined the promoter methylation status of 10 biologically significant tumor suppressor and cancer genes in 100 kidney tumors (50 clear cell, 20 papillary, 6 chromophobe, 5 collecting duct, 5 renal cell unclassified, 7 oncocytoma, 6 transitional cell carcinomas of the renal pelvis, and 1 Wilms’ tumor) by methylation-specific PCR. The hypermethylation profile was examined with regard to clinicopathological characteristics of the kidney cancer patients.

Results: Hypermethylation of one or more genes was found in 93 (93%) of 100 tumors. A total of 33% of kidney tumors had one gene, 35% two genes, 14% three genes, and 11% four or more genes hypermethylated. The frequency of hypermethylation of the 10 genes in the 100 tumor DNAs was VHL 8% (all clear cell), p16^INK4a 10%, p14^ARF 17%, APC 14%, MGMT 7%, GSTP1 12%, RARß2 12%, RASSF1A 45%, E-cadherin 11%, and Timp-3 58%. Hypermethylation was observed in all of the histological cell types and grades and stages examined. No hypermethylation was observed in specimens of normal kidney or ureteral tissue from 15 patients. Hypermethylation of VHL was specific to clear cell tumors. RASSF1A methylation was detected at a significantly higher frequency in papillary renal cell tumors and in high-grade tumors of all cell types. MGMT methylation was more frequent in nonsmokers. Simultaneous methylation of five or more genes was observed in 3 (3%) of 100 tumors and may indicate a methylator phenotype in kidney cancer. In addition, the CpG island in the promoter of the fumarate hydratase (FH) tumor suppressor gene was bisulfite sequenced and was found to be unmethylated in 15 papillary renal tumors.

Conclusions: Promoter hypermethylation is common, can occur relatively early, may disrupt critical pathways, and, thus, likely plays an important role in kidney tumorigenesis. A hypermethylation profile may be useful in predicting a patient’s clinical outcome and provide molecular markers for diagnostic and prognostic approaches to kidney cancer.

This article has been cited by other articles:

				I. Waldhauer, D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, and A. Steinle Tumor-Associated MICA Is Shed by ADAM Proteases Cancer Res., August 1, 2008; 68(15): 6368 - 6376. [Abstract] [Full Text] [PDF]

				I. Peters, B. Vaske, K. Albrecht, M. A. Kuczyk, U. Jonas, and J. Serth Adiposity and Age are Statistically Related to Enhanced RASSF1A Tumor Suppressor Gene Promoter Methylation in Normal Autopsy Kidney Tissue Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2526 - 2532. [Abstract] [Full Text] [PDF]

				J. S. Fridman, E. Caulder, M. Hansbury, X. Liu, G. Yang, Q. Wang, Y. Lo, B.-B. Zhou, M. Pan, S. M. Thomas, et al. Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1892 - 1902. [Abstract] [Full Text] [PDF]

				M. D. Williams, N. Chakravarti, M. S. Kies, S.-I. Maruya, J. N. Myers, J. C. Haviland, R. S. Weber, R. Lotan, and A. K. El-Naggar Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors Clin. Cancer Res., December 15, 2006; 12(24): 7353 - 7358. [Abstract] [Full Text] [PDF]

				F. Christoph, S. Weikert, C. Kempkensteffen, H. Krause, M. Schostak, J. Kollermann, K. Miller, and M. Schrader Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications Clin. Cancer Res., September 1, 2006; 12(17): 5040 - 5046. [Abstract] [Full Text] [PDF]

				M. J. Worsham, K. M. Chen, V. Meduri, A. O. H. Nygren, A. Errami, J. P. Schouten, and M. S. Benninger Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 668 - 677. [Abstract] [Full Text] [PDF]

				I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res., May 15, 2006; 66(10): 5021 - 5028. [Abstract] [Full Text] [PDF]

				R. E. Banks, P. Tirukonda, C. Taylor, N. Hornigold, D. Astuti, D. Cohen, E. R. Maher, A. J. Stanley, P. Harnden, A. Joyce, et al. Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer Cancer Res., February 15, 2006; 66(4): 2000 - 2011. [Abstract] [Full Text] [PDF]

				Z. Liu, L.-E Wang, L. Wang, K. H. Lu, G. B. Mills, M. L. Bondy, and Q. Wei Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4968 - 4976. [Abstract] [Full Text] [PDF]

				M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al. Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4598 - 4606. [Abstract] [Full Text] [PDF]